A NEW METHOD FOR THE PREPARATION OF DRUG CONTAINING POLYLACTIC ACID MICROPARTICLES WITHOUT USING ORGANIC-SOLVENTS

被引:31
作者
WICHERT, B [1 ]
ROHDEWALD, P [1 ]
机构
[1] UNIV MUNSTER,INST PHARMAZEUT CHEM,W-4400 MUNSTER,GERMANY
关键词
MICROPARTICLES; D; L-POLYLACTIC ACID; MELTING METHOD; SUSTAINED RELEASE; VINPOCETINE;
D O I
10.1016/0168-3659(90)90167-R
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Microparticles of D,L-polylactic acid (PLA) prepared by a new method (melting method) were compared with microparticles obtained by the solvent evaporation/extraction method. For particle preparation by the melting method, the matrix polymer (D,L-PLA, MW 2000 or 16000) was melted in presence of the drug vinpocetine, a new neurotropic agent, to obtain a homogeneous mixture. After emulsification of the melt in a hot aqueous solution, microparticles were isolated by either pouring the hot emulsion into ice-water or spray drying. electron microscopy revealed a smooth surface of the D,L-PLA 2000 particles isolated by spray drying, whereas D,L-PLA 16000 microparticles and D,L-PLA 2000 isolated by centrifugation showed a rough surface. The mean diameter ranged from 2 to 22-mu-m, depending on the MW of the polymer and the isolation method. A faster drug release could be achieved by increasing the drug content or by addition of polyethylene glycol to D,L-PLA. These two factors are useful for influencing the release characteristics. For oral application an ideal retardation could be achieved with D,L-PLA 2000, whereas D,L-PLA 16000 microparticles showed a prolonged release characteristic over some days and should therefore be useful for intramuscular and subcutaneous administration. During the preparation of microparticles by melting, the MW was reduced by ca. 12%, as ascertained by end group titration. HPLC analysis demonstrated that the drug was stable during the preparation process.
引用
收藏
页码:269 / 283
页数:15
相关论文
共 28 条
[1]  
Walker, Turkes, Turkes, Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist Zoaldex, J. Endocrinol., 103, pp. R1-R4, (1984)
[2]  
Del Pozo, Schluter, Neusch, Pharmacokinetics of a long-acting bromocriptine preparation Parloder LAt, Acta Obstet. Gynecol. Scand., 66, pp. 61-62, (1987)
[3]  
Fricke, Neue Arzneimittel 1986/1987, (1987)
[4]  
Miller, Brady, Cutright, Degradation rates of oral resorbable implants (polylactates and polyglycolated): Rate modification with changes in PLA/PLGA copolymer ratios, J. Biomed. Mater. Res., 11, pp. 711-719, (1977)
[5]  
Fischer, Boertz, Davis, Koshla, Cawello, Sandrock, Cordes, Investigation of the gastrointestinal transit and in vivo drug release of isosorbide-5-nitrate pellets, Pharm. Res., 4, pp. 480-485, (1987)
[6]  
Stricker, Physikalische Chemie, (1987)
[7]  
Bodmeier, McGinity, Polylactic acid microspheres containing quinidine base and quinidine sulfate prepared by the solvent evaporation technique, J. Microencapsulation, 4, pp. 279-297, (1987)
[8]  
Brophy, Deasy, In vitro and in vivo studies on biodegradable polyester microparticles containing sulphamethiazole, Int. J. Pharm., 29, pp. 223-231, (1986)
[9]  
Shell, Controlled-release biodegradable drug delivery systems with rapid-dispersing matrix and controlledrelease microcapsules, (1978)
[10]  
Smith, Hunneyball, Evaluation of poly (lactic acid) as a biodegradable drug delivery system for parenteral administration, Int. J. Pharm., 30, pp. 215-220, (1986)